BioMérieux Reports 6% Organic Growth in 2025 and Raises Its Targets
In vitro diagnostics group bioMérieux recorded a revenue of 4,070 million euros in 2025, marking an organic growth of 6.2%. The contributory operating income increased by 16% at constant exchange rates, achieving a margin of 17.9%, while the adjusted net earnings per share grew by 9% to 4.64 euros.
Steady Performance Aligned with Strategic Plan GO-28
BioMérieux delivered performances in line with its strategic plan GO-28 during the fiscal year 2025. The consolidated revenue stood at 4,070 million euros, up from 3,980 million in 2024, an organic increase of 6.2% at constant exchange rates and scope. This growth was driven by the group's four strategic engines: non-respiratory BIOFIRE panels grew by 10% to reach 598 million euros, SPOTFIRE surged by 84% in value to generate 168 million euros with a doubled installed base of 6,400 instruments, Microbiology increased by 4% despite a decline in China, and Industrial Applications saw robust growth of 9%. BIOFIRE respiratory panels saw a 1% organic increase, reflecting an epidemiological activity broadly comparable to 2024. In the fourth quarter, organic growth was 3.5%, impacted by a decline in China and a decrease in respiratory panels against a high comparison base.
Significant Increase in Contributory Operating Income
The contributory operating income reached 728 million euros in 2025, up by 16% at constant exchange rates and scope, corresponding to a sales margin of 17.9%, an improvement of 160 basis points. The gross margin was established at 56.7% of revenue, progressing organically by 90 basis points, supported by a favorable product mix and efficiency initiatives under the GO-28 plan. Commercial and general expenses accounted for 27.3% of revenue, organically growing by 4.1%, while R&D expenditures amounted to 507 million euros, representing 12.5% of revenue. The net income attributable to the group decreased by 8% to 398 million euros, due to a partial impairment of 141 million euros on the VITEK REVEAL technology, linked to slower market development than anticipated. The adjusted net income, excluding non-recurring items, grew by 9.4% to 552 million euros.
Optimistic Outlook for 2026 with Revised Dividend
For 2026, bioMérieux anticipates a revenue growth between 5% and 7% at constant exchange rates and scope, driven by progress in the four strategic engines. The contributory operating income is expected to increase by at least 10% at constant exchange rates and scope, subject to negative currency effects estimated between 50 and 60 million euros. The group has raised its dividend to 0.98 euros per share, up by 9%, and confirms the ambitions of its GO-28 plan targeting a sales growth of about 7% in compound annual growth rate over 2024-2028 and an increase in ROCC of at least 10% each year. In terms of social responsibility, bioMérieux has strengthened its CSR objectives for 2028 and accelerated the reduction of its absolute greenhouse gas emissions, from minus 13% to minus 28% compared to 2019.
